THE DEVELOPMENT OF HIGH-DOSE CHEMOTHERAPY INDIVIDUALIZATION OF OVARIAN-CANCER PATIENTS

By means of MTT-in vitro assay the drug sensitivity (for CDDP, CBDCA, adriablastin, Thio-Tepa and 5-Fluorouracil) of human ovarian tumor cel ls (70 patients) was studied. 325 dose-effect curves were analyzed. It was found that there were drug-resistant tumors even if cytostatics w ere used at the doses which three-times exceeded the therapeutically e quivalent ones. Fog all the doses of cytostatics used (1.0-3.0 therape utically equivalent), the number of drug-resistant tumors was minimal for CBDCA and maximal for 5-Fluorouracil. These data provide an eviden ce for the expediency of laboratory study of dose-dependent drug sensi tivity for high-dose chemotherapy of ovarian cancer patients.